These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 21921845)

  • 21. [One-year combination therapy de novo of adefovir dipivoxil and lamivudine for decompensated cirrhosis related to HBV].
    Mo GS; Wu ZL; Zhang JL; Hhang ZG; Cai JG; Jie ZH; Wu XG; Shi JP
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Apr; 25(2):129-31. PubMed ID: 21863638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
    Papatheodoridis GV; Dimou E; Dimakopoulos K; Manolakopoulos S; Rapti I; Kitis G; Tzourmakliotis D; Manesis E; Hadziyannis SJ
    Hepatology; 2005 Jul; 42(1):121-9. PubMed ID: 15962291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy.
    Arora G; Keeffe EB
    Rev Gastroenterol Disord; 2007; 7(2):63-73. PubMed ID: 17597674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
    Sponseller CA; Bacon BR; Di Bisceglie AM
    Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
    Hosaka T; Suzuki F; Kobayashi M; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Liver Int; 2010 Nov; 30(10):1461-70. PubMed ID: 20840396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
    Toyoda H; Kumada T; Tada T; Sone Y; Fujimori M
    J Vasc Interv Radiol; 2012 Mar; 23(3):317-22.e1. PubMed ID: 22265248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    Intervirology; 2008; 51(6):385-93. PubMed ID: 19229115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
    Villeneuve JP; Condreay LD; Willems B; Pomier-Layrargues G; Fenyves D; Bilodeau M; Leduc R; Peltekian K; Wong F; Margulies M; Heathcote EJ
    Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis.
    Nishida T; Kobashi H; Fujioka S; Fujio K; Takaguchi K; Ikeda H; Kawaguchi M; Ando M; Araki Y; Higashi T; Shoji B; Takaki A; Iwasaki Y; Sakaguchi K; Shiratori Y; Yamamoto K
    J Gastroenterol Hepatol; 2008 May; 23(5):794-803. PubMed ID: 18086120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
    Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
    Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B.
    van der Poorten D; Prakoso E; Khoo TL; Ngu MC; McCaughan GW; Strasser SI; Lee AU
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1500-5. PubMed ID: 17683493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.
    Fontana RJ; Keeffe EB; Carey W; Fried M; Reddy R; Kowdley KV; Soldevila-Pico C; McClure LA; Lok AS;
    Liver Transpl; 2002 May; 8(5):433-9. PubMed ID: 12004342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Lai CJ; Terrault NA
    Gastroenterol Clin North Am; 2004 Sep; 33(3):629-54, x-xi. PubMed ID: 15324948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
    Liang Y; Jiang J; Su M; Liu Z; Guo W; Huang X; Xie R; Ge S; Hu J; Jiang Z; Zhu M; Wong VW; Chan HL
    Aliment Pharmacol Ther; 2011 Aug; 34(3):344-52. PubMed ID: 21671967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
    Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
    Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of patients with decompensated HBV cirrhosis.
    Fontana RJ
    Semin Liver Dis; 2003 Feb; 23(1):89-100. PubMed ID: 12616454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.
    Hyun JJ; Seo YS; Yoon E; Kim TH; Kim DJ; Kang HS; Jung ES; Kim JH; An H; Kim JH; Yim HJ; Yeon JE; Lee HS; Byun KS; Um SH; Kim CD; Ryu HS
    Liver Int; 2012 Apr; 32(4):656-64. PubMed ID: 22099071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.